15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 其他肝脏问题 富含水果的饮食对非酒精性脂肪肝患者肝脏生物标志物、胰 ...
查看: 194|回复: 1
go

富含水果的饮食对非酒精性脂肪肝患者肝脏生物标志物、胰

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30441 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

发表于 2022-6-17 20:26 |显示全部帖子
富含水果的饮食对非酒精性脂肪肝患者肝脏生物标志物、胰岛素抵抗和血脂的影响:一项随机临床试验
法洪德阿拉米
, 穆罕默德·阿里扎德
& 卡姆兰·沙特里
2022年1月31日接收,2022年4月24日接受,在线发表:2022年6月16日

    下载引文 https://doi.org/10.1080/00365521.2022.2071109 CrossMark Logo CrossMark

抽象的
背景

尽管已证实可以改善非酒精性脂肪肝 (NAFLD) 的饮食方法,但水果对 NAFLD 的影响尚不清楚。本研究旨在调查富含水果的饮食 (FRD) 对 NAFLD 患者肝脏脂肪变性、肝酶、胰岛素抵抗和血脂谱的影响。
方法

八十名患有 NAFLD 的成年人参加了这项随机对照试验。参与者被随机分配到每天食用至少 4 份水果的 FRD 组或每天食用少于 2 份水果的对照组。脂肪变性的等级、血清肝酶水平,包括丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、碱性磷酸酶(ALP)和γ-谷氨酰转移酶(GGT)、总胆固醇(TC)、甘油三酯(TG)、低-在基线和研究结束时测量密度脂蛋白 (LDL)、高密度脂蛋白 (HDL)、葡萄糖和胰岛素抵抗的稳态模型评估 (HOMA-IR)。
结果

干预6 个月后,FRD组BMI显着升高(31.40 ± 2.61 vs. 25.68 ± 2.54,p < .001),WC(113.5 ± 10.7 vs. 100.5 ± 7.5,p < .001),等级为,Alt(89.1±92.9 vs. 32.0±19.2,p <.001),AST(74.5±107.8 vs. 24.0±8.5,p <.001),ALP(273.4±128.5 vs. 155.0±43.9,p <.001,p <.001,p <.001 ),GGT(92.7±16.2 vs. 21.2±7.7,p <.001),TC(206.1±40.5 vs. 172.7±42.4,p <.01),LDL(126.9±32.3 vs. 99.8±29.8,p <。 001)、葡萄糖(115.5 ± 30.0 vs. 97.7 ± 19.0,p < .01)和胰岛素抵抗(7.36 ± 4.37 vs. 2.66 ± 1.27,p < .001)和低 HDL(41.4±8.9 vs. 53) 15.1, p < .001) 与对照组相比。调整 BMI 和卡路里摄入量并没有改变结果。
结论

本研究的结果表明,每天食用超过 4 份水果会加剧 NAFLD 患者的脂肪变性、血脂异常和血糖控制。需要进一步的研究来确定水果对 NAFLD 影响的潜在机制。
临床试验注册

该试验已在伊朗随机临床试验网站注册,IRCT 注册号为。 IRCT20201010048982N1 于 2020 年 10 月 15 日。

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30441 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

发表于 2022-6-17 20:26 |显示全部帖子
The effect of a fruit-rich diet on liver biomarkers, insulin resistance, and lipid profile in patients with non-alcoholic fatty liver disease: a randomized clinical trial
Farkhondeh Alami
, Mohammad Alizadeh
& Kamran Shateri
Received 31 Jan 2022, Accepted 24 Apr 2022, Published online: 16 Jun 2022

    Download citation https://doi.org/10.1080/00365521.2022.2071109 CrossMark Logo CrossMark

Abstract
Background

Despite confirmed dietary approaches to improve the Non-Alcoholic Fatty Liver Disease (NAFLD), the effect of fruits on NAFLD is not clear. The present study aimed to investigate the effect of a fruit rich diet (FRD) on liver steatosis, liver enzymes, Insulin resistance, and lipid profile in patients with NAFLD.
Methods

Eighty adults with NAFLD participated in this randomized controlled trial. The participants were randomly assigned to the FRD group with consumption of at least 4 servings of fruits daily or the control group with fruits consumption of less than 2 servings/day. The grade of steatosis, serum levels of liver enzymes including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT), total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), glucose, and homeostatic model assessment for insulin resistance (HOMA-IR) were measured at the baseline and at the end of the study.
Results

After 6 months of intervention, the FRD group had significantly higher BMI (31.40 ± 2.61 vs. 25.68 ± 2.54, p < .001), WC (113.5 ± 10.7 vs. 100.5 ± 7.5, p < .001), the grade of steatosis, ALT (89.1 ± 92.9 vs. 32.0 ± 19.2, p < .001), AST (74.5 ± 107.8 vs. 24.0 ± 8.5, p < .001), ALP (273.4 ± 128.5 vs. 155.0 ± 43.9, p < .001), GGT (92.7 ± 16.2 vs. 21.2 ± 7.7, p < .001), TC (206.1 ± 40.5 vs. 172.7 ± 42.4, p < .01), LDL (126.9 ± 32.3 vs. 99.8 ± 29.8, p < .001), glucose (115.5 ± 30.0 vs. 97.7 ± 19.0, p < .01), and insulin resistance (7.36 ± 4.37 vs. 2.66 ± 1.27, p < .001), and lower HDL (41.4 ± 8.9 vs. 53.8 ± 15.1, p < .001) compared to the control group. Adjusting for BMI and calorie intake did not change the results.
Conclusion

The results of the present study indicated that consumption of fruits more than 4 servings/day exacerbates steatosis, dyslipidemia, and glycemic control in NAFLD patients. Further studies are needed to identify the underlying mechanisms of the effects of fruits on NAFLD.
Clinical trial registration

This trial was registered at Iranian randomized clinical trial website with IRCT registration no. IRCT20201010048982N1on October 15, 2020.
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-3-29 00:07 , Processed in 0.014183 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.